Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1601-1620 of 2,120 trials

Antibiotics in Cerebrospinal Fluid: A Study in Children

We are examining how well antibiotics work in the cerebrospinal fluid of children with an external ventricular drain. This research aims to improve treatment for infections in these patients.

Patients with External Ventricular Drain>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Alcohol-Associated Hepatitis: Alpha-1 Antitrypsin Treatment

We are studying whether intravenous Alpha-1 Antitrypsin can reduce inflammation in patients with severe alcohol-associated hepatitis. The trial also looks at its safety and effects on liver health.

Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Atenativ for Congenital Antithrombin Deficiency During Surgery

We are studying how Atenativ may help patients with congenital antithrombin deficiency during surgical procedures or childbirth. The trial looks at its safety, effectiveness, and how the body processes the medication.

Congenital Antithrombin Deficiency>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsHematologyInternal Medicine

Tarlatamab for Advanced Small-Cell Lung Cancer

We are studying a new treatment for patients with metastatic or locally advanced small-cell lung cancer and other neuroendocrine carcinomas. The goal is to see how well it works and to understand its safety.

Metastatic Small Cell Lung Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Brain Metastases Detection: PET-DOPA Imaging Study

We are studying a new imaging method to detect untreated brain metastases in patients with lung, breast, or melanoma cancer. This research aims to improve how we identify and understand these tumors.

Brain Metastases from Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Chickenpox Vaccine Safety Study for Young Children

We are evaluating the safety of a new chickenpox vaccine for healthy children aged 12 to 15 months. This study compares it with an existing vaccine when given with other routine immunizations.

Chickenpox6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Biliary Tract Cancer: Ivonescimab vs. FOLFOX

We are testing a new treatment, ivonescimab, against standard chemotherapy for patients with advanced biliary tract cancer. The goal is to see if it helps patients live longer and feel better.

Advanced Biliary Tract Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Histiocytosis: Fludeoxyglucose (18F-FDG) Imaging Study

We are examining how fludeoxyglucose (18F-FDG) in PET/CT scans can help monitor juvenile patients with histiocytosis. The study will assess its safety and potential benefits for those with specific mutations.

Erdheim-Chester DiseaseLangerhans Cell SarcomaRosai-Dorfman Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOtolaryngology

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Mitral Valve Surgery: Landiolol Study

We are investigating whether Landiolol can help improve heart function and reduce complications after mitral valve surgery. This study looks at its effects on heart health and recovery in patients undergoing this procedure.

Low Cardiac Output Syndrome>2 yearsMonitoring phase (IV)Investigational MedicinesCardiologyInternal Medicine

Lung Cancer: Pembrolizumab Maintenance Study

We are studying whether continuing pembrolizumab treatment helps patients with stage IV lung cancer maintain disease control after initial chemotherapy. This trial will also look at the quality of life and side effects experienced by participants.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Acute Cholecystitis: Antibiotic Treatment Comparison

We are studying whether a single dose of antibiotics before gallbladder surgery is as effective as continuous antibiotics in preventing infections. This trial aims to improve patient outcomes during and after surgery.

Acute Cholecystitis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology